Reported trial results for Vitiligo

25 trials have reported results.

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

• NCT05750823 · results posted 20 March 2026

  According to the results reported on ClinicalTrials.gov, this trial enrolled 49 adults who used a cream called ruxolitinib 1.5% applied twice daily to areas of genital vitiligo — a condition where patches of skin lose their colour. There was only one group, meaning everyone received the same cream; there was no comparison group receiving a dummy (placebo) treatment. Of the 49 people who started, 35 completed the trial and 14 did not finish. The trial ran for 48 weeks and tracked several things, including how noticeable participants felt their vitiligo was compared to when they started, how doctors rated the severity of the condition, and how much body surface area was affected. The reported data shows that for the main measure — the proportion of participants who said their genital vitiligo was "a lot less noticeable" or "no longer noticeable" at week 48 compared to the start — 27% of participants reached that point. For a doctor-rated scale (where a score of 0 meant clear skin and 1 meant almost clear), about 10.8% of participants achieved that result at week 48. When looking at the whole body (not just the genital area), the reported data shows that at week 24 around 24.4% of participants had at least a 50% improvement in a standardised body-wide scoring system, rising to 35.1% at week 48; a higher bar of 75% improvement was reached by 7.3% at week 24 and 16.2% at week 48. Regarding the genital skin surface area affected, the reported numbers suggest a small reduction over time, though the data as submitted contained multiple measurement entries. For unwanted medical events (called adverse events) that occurred during the treatment period, 19 out of 49 participants reported at least one such event; the data does not break down what those events were. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT06113328 · results posted 17 March 2026

  According to the results reported on ClinicalTrials.gov, this trial (NCT06113328) tested an investigational medicine called MK-6194 in people with vitiligo — a skin condition where patches of skin lose their colour. A total of 169 participants took part in the initial double-blind phase, split into three groups: 57 received MK-6194 by injection every two weeks (Q2W), 55 received it every four weeks (Q4W), and 57 received a placebo (a dummy treatment with no active ingredient). Those who completed that phase could continue into an extension period. The trial was primarily measuring changes in the extent of skin colour loss on the face and across the whole body, as well as tracking any unwanted medical events (called adverse events) that occurred during the study. The reported data shows that after 24 weeks, the facial skin colour loss score (called F-VASI — a scale where a lower score means less affected skin) changed by an average of −4.55% in the every-two-weeks MK-6194 group, −12.13% in the every-four-weeks group, and −4.01% in the placebo group. For the whole-body score (T-VASI), the reported changes were −1.69%, −9.08%, and +0.78% respectively — meaning the placebo group's score nudged slightly upward (suggesting a small increase in skin involvement on average). Regarding unwanted medical events, the reported data shows that 51 out of 57 participants in the every-two-weeks group, 47 out of 55 in the every-four-weeks group, and 44 out of 57 in the placebo group experienced at least one adverse event. The number of participants who stopped treatment because of an adverse event was 9, 5, and 1 in those same groups respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT04953338 · results posted 2 December 2025

  According to the results reported on ClinicalTrials.gov, this study looked at whether adults diagnosed with vitiligo (a skin condition that causes patches of skin to lose their colour) were more likely to be recorded as having certain mental health conditions compared to adults without vitiligo. The study included 7,224 people with vitiligo (the "cases" group) and 28,880 people without vitiligo (the "controls" group), and no participants were recorded as dropping out. The reported data shows that among the vitiligo group, 1,018 participants had a recorded depressive episode, 1,093 had recurrent depressive disorder, and 569 had an anxiety disorder. In the much larger control group, the corresponding numbers were 4,007, 4,305, and 2,031 respectively. The study also reported figures related to the relative likelihood — sometimes called a "hazard ratio," which is a way of comparing how often something occurs in one group versus another over time — of developing these conditions. For depressive episodes, 157 cases and 501 controls were included in that comparison; for recurrent depressive disorder, 113 cases and 312 controls; and for anxiety disorder, 122 cases and 382 controls. The specific hazard ratio values themselves were not included in the submitted data, so those figures cannot be described here. The reported data shows raw counts of how many people in each group were recorded with these conditions, alongside participant numbers used in the time-based comparisons. No efficacy or safety conclusions are drawn here, and these numbers alone do not tell us what caused any of the recorded differences between the groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT04338581 · results posted 17 November 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT04338581) enrolled 60 people with vitiligo — 40 received the investigational treatment AMG 714 and 20 received a placebo (an inactive comparison treatment). Of those, 34 in the AMG 714 group and 16 in the placebo group completed the study. The trial was measuring changes in the amount of facial skin affected by vitiligo, using a scoring tool called the Facial Vitiligo Area Scoring Index (F-VASI), which rates the extent and degree of colour loss on the face. The main question the trial set out to answer was what proportion of participants showed at least a 35% improvement in their facial vitiligo score by 24 weeks. The reported data shows that at week 24 — the main measurement point — 15% of participants in the AMG 714 group met the threshold of at least a 35% improvement in their facial vitiligo score, compared with approximately 5% in the placebo group. For the secondary measurements taken at additional time points, the reported data shows that by week 48 (roughly 11 months), around 40% of the AMG 714 group had reached that 35% improvement threshold, compared with about 26% of the placebo group. When a stricter threshold of 50% improvement was used, the reported figures at week 48 were 35% of the AMG 714 group versus 26% of the placebo group. At the highest thresholds measured — 75% and 90% improvement — the reported data shows that no participants in the placebo group reached those levels at any time point, while small proportions of the AMG 714 group were recorded as reaching them by week 48 (20% and 7.5% respectively). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT06097494 · results posted 17 March 2025

  According to the results reported on ClinicalTrials.gov, this study looked at records from 39,374 people in total — 7,890 people with vitiligo (a skin condition where patches of skin lose their colour) and 31,484 people without vitiligo who served as a comparison group. The study was measuring whether people with vitiligo were more or less likely to have recorded diagnoses of depression or anxiety, and whether there were differences in how often both groups visited their GP, were referred to a skin specialist (dermatologist), or were referred for mental health support. The reported data shows that, among people with vitiligo, 1,412 had a recorded depression event and 708 had a recorded anxiety event, compared to 5,395 and 2,430 respectively in the much larger comparison group. When looking at depression or anxiety combined, 1,614 events were recorded in the vitiligo group versus 6,064 in the comparison group. The reported data also shows that the vitiligo group had 134,207 recorded GP visits compared to 439,633 in the comparison group, and 311 mental health referrals compared to 1,191 in the comparison group. Note that the two groups are very different in size, so these raw numbers alone do not directly tell us whether one group experienced these events more or less often per person — the study used statistical methods to account for this, but the adjusted figures themselves were not included in the data reported here. Regarding specialist skin referrals, the reported data shows that approximately 20% of people with vitiligo had a recorded referral to a dermatologist within two years of their diagnosis. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT05247489 · results posted 20 February 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT05247489) enrolled 55 people with vitiligo — 20 in a group using ruxolitinib 1.5% cream twice daily on its own, and 35 in a group using the same cream combined with a type of light therapy called narrowband ultraviolet B (NB-UVB). The trial mainly looked at how much the overall extent of vitiligo (measured using a scoring system called T-VASI, where a lower score means less affected skin) changed over 48 weeks. By the end of the study, 6 people in the cream-only group and 26 in the combination group had completed the trial; 14 and 9 participants respectively did not finish. The reported data shows that at the start of the study, average T-VASI scores were 6.58 (cream-only group) and 6.87 (combination group). By week 48, both groups showed a reduction in their scores — down by about 3.43 points in the cream-only group and 3.46 points in the combination group. For the face specifically, the reported data shows that by week 48, 100% of participants remaining in the cream-only group and 87.5% in the combination group had achieved at least a 50% improvement in their facial vitiligo score. Larger improvements (at least 90% improvement in facial score) were reported in 50% of the cream-only group and 34.4% of the combination group at that same point. For whole-body scoring, at least a 50% improvement by week 48 was reported in 66.7% of the cream-only group and 34.4% of the combination group. Regarding unwanted events that occurred during treatment, 9 out of 20 participants in the cream-only group and 21 out of 35 in the combination group were reported to have experienced at least one such event; the specific nature of those events was not detailed in the data provided here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT04969419 · results posted 14 January 2025

  According to the results reported on ClinicalTrials.gov, this study looked at whether adults with vitiligo (a skin condition that causes patches of skin to lose their colour) were more or less likely to develop new skin cancers compared to people without vitiligo. The study tracked 15,156 people with vitiligo (called "cases") and 60,615 people without vitiligo (called "controls" — a comparison group matched to the cases). The skin cancers being counted included melanoma, squamous cell carcinoma, and basal cell carcinoma. The reported data shows that, overall, 133 people in the vitiligo group developed a new skin cancer, compared with 812 people in the control group. When broken down by sex, the reported figures show 78 female vitiligo participants developed skin cancer versus 429 female controls, and 55 male vitiligo participants versus 383 male controls. Looking at age groups, the reported numbers were: 11 cases versus 72 controls among those under 45; 42 cases versus 315 controls among those aged 45–64; and 80 cases versus 425 controls among those aged 65 and over. No additional statistical analyses (such as calculations adjusting for other factors that might influence the results) were included in the data submitted to ClinicalTrials.gov, so those figures are not available to report here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04374435 · results posted 5 September 2024

  According to the results reported on ClinicalTrials.gov, this trial enrolled 17 people in total across three groups. Seven participants received a skin cell transplant procedure (known as MKTP) using a surgical blade, seven received the same type of transplant using a negative pressure instrument (a device that uses suction), and three received a different technique called suction blister grafting without cell separation. All 17 participants completed the trial. The trial was measuring changes in the affected skin area in people with vitiligo — a condition where patches of skin lose their colour — using photography and a scoring system called VASI (Vitiligo Area Scoring Index), which tracks how much of the skin is affected. The reported data shows that, when looking at the number of participants who showed a measurable change in their affected body surface area, 6 out of 7 participants were counted in the surgical blade group, 4 out of 7 in the negative pressure instrument group, and 2 out of 3 in the suction blister group. For the VASI score — where a negative number means the affected area got smaller and a positive number means it got larger — the surgical blade group showed an average change of −23.0%, the negative pressure instrument group showed −10.2%, and the suction blister group showed −0.33%. Regarding the secondary measures, the reported data shows that all 17 participants across all three groups were recorded as having healed at both the donor and graft sites within one week, and zero participants in any group were recorded as having experienced complications. It is worth noting that this was a very small trial with just 17 participants across three groups, so the numbers above reflect a limited number of people. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04811131 · results posted 12 July 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT04811131) enrolled 114 adults across four groups to test combinations of an investigational product (referred to as "Active IP" or a matched dummy "Vehicle") alongside either real light therapy (phototherapy) or a sham (fake) version of it. The four groups were: Active IP with real phototherapy (34 people), Active IP with sham phototherapy (37 people), vehicle with real phototherapy (31 people), and vehicle with sham phototherapy (12 people). The trial was measuring changes in facial vitiligo — a skin condition that causes loss of pigment — using a standardised scoring tool called the F-VASI, which rates how much of the face is affected and how deeply pigment has been lost. The reported data shows that the trial was ended early, and as a result, the primary goal — measuring how many participants achieved at least a 75% improvement in their facial vitiligo score by week 24 — was not able to be reported with any numbers. Several other planned measurements, including changes in affected skin surface area, how noticeable the vitiligo appeared, quality of life, and participants' own impressions of change, were also not assessed due to the early stopping of the trial. For the one secondary outcome where some figures were recorded — the percentage change in F-VASI score at various earlier time points — the reported data shows reductions in scores (meaning less affected skin) across most groups over time. The group receiving both active treatments together showed the largest reported reductions (for example, around -57% at one time point and around -63% at another), while the group receiving both dummy treatments showed smaller or no reductions. However, because the trial ended early and not all participants completed the study, these figures should be understood as incomplete. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT03270241 · results posted 9 January 2024

  According to the results reported on ClinicalTrials.gov, this trial involved 10 participants, all of whom completed the study with no dropouts. The trial was looking at a type of light treatment called narrowband ultraviolet B (NB-UVB) phototherapy for vitiligo — a skin condition where patches of skin lose their colour. Specifically, the researchers were examining changes happening at a cellular and molecular level in both affected and unaffected skin, by measuring certain biological markers (proteins and signalling molecules in the skin) before and after the light treatment. The reported data shows that the primary outcome measure — which tracked molecular markers in the skin, including substances known as KIT receptor, stem cell factor (SCF), tumour necrosis factor-alpha (TNF-alpha), and interleukin-1 (IL-1) — did not have any numerical results submitted to ClinicalTrials.gov. In other words, while the study measured these markers, no actual figures or results for these measurements were reported in the structured data available on the registry. Because no outcome numbers were provided in the submitted results, it is not possible to describe what the measurements showed. The data was not reported rather than indicating any particular finding. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT04896385 · results posted 7 December 2023

  According to the results reported on ClinicalTrials.gov, this trial enrolled 60 participants in total — 41 were assigned to ruxolitinib cream 1.5% (applied twice daily) and 19 to a vehicle cream (a cream with no active ingredient, used as a comparison). The trial ran in two stages: a 24-week double-blind period (where neither participants nor researchers knew who received which cream), followed by a 28-week extension period in which all participants used the active ruxolitinib cream. The trial was primarily measuring changes in a skin immune marker called CXCL10 — a protein linked to the inflammation seen in vitiligo — to understand what was happening at a biological level in the skin. The reported data shows that, at weeks 4, 12, and 24 of the double-blind period, participants using the ruxolitinib cream had average reductions in CXCL10 of approximately 21%, 18%, and 13% from their starting levels respectively. In contrast, participants using the vehicle cream showed average increases in CXCL10 of approximately 8%, 21%, and 22% over those same time points. A secondary measure looked at whether CXCL10 levels tracked alongside standard visual scoring of vitiligo patches on the face and body; the reported correlation figures (a number between -1 and +1 indicating how closely two things move together) were -0.34 and -0.43 for the ruxolitinib group and 0.15 and 0.02 for the vehicle group. The trial also counted how many participants experienced any new or worsening medical events after starting treatment (called treatment-emergent adverse events): during the double-blind period, 19 of 41 participants in the ruxolitinib group and 7 of 19 in the vehicle group reported at least one such event. One participant in the ruxolitinib group had a more serious event (graded "severe" or higher) during this period; none did in the vehicle group. During the extension period, 12 of 37 continuing ruxolitinib participants and 3 of 14 who switched from vehicle to ruxolitinib reported at least one such event, with one serious event recorded in the switched group and none in the continuing group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT04547998 · results posted 21 September 2023

  According to the results reported on ClinicalTrials.gov, this trial (NCT04547998) enrolled 50 adults with vitiligo — a skin condition that causes loss of skin colour in patches. Participants were split into two equal groups of 25. One group received ultraviolet B (UVB) light therapy alone (the control group), while the other received a combination treatment involving ablative laser resurfacing (a procedure that removes the outer skin layer), a cell-spray technique called RECELL, and UVB light therapy. All 50 participants completed the trial. The main thing the trial was measuring was how many treated skin areas achieved at least 80% return of skin colour (repigmentation). The reported data shows that, for the primary measure, none (0 out of 25) of the study areas in the UVB-only group reached 80% or more repigmentation, while 9 out of 25 study areas in the combination treatment group did. For the secondary measure looking at repigmentation categories across all levels, the reported data shows that in the UVB-only group, 5 areas had 0–25% repigmentation, 13 had 26–50%, 4 had 51–79%, and 3 had 80–100%, with none achieving full (100%) repigmentation. In the combination group, 3 areas had 0–25%, 6 had 26–50%, 2 had 51–79%, 5 had 80–100%, and none achieved full repigmentation. Regarding how well the returning colour matched the surrounding skin, the reported data shows that in the UVB-only group, 0 areas were rated "poor", 4 "moderate", 12 "good", and 4 "excellent". In the combination group, 1 was rated "poor", 6 "moderate", 9 "good", and 6 "excellent." These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04530344 · results posted 19 July 2023

  According to the results reported on ClinicalTrials.gov, this trial (NCT04530344) enrolled 458 participants in total across four groups. It was an extension study for people with vitiligo — a skin condition that causes loss of skin colour — who had already taken part in a previous trial using ruxolitinib 1.5% cream or a dummy (vehicle) cream applied twice daily. The trial was measuring how long it took for facial skin improvements to fade, and how many participants maintained improvements in their facial vitiligo over the extension period. Skin improvement was tracked using a scoring system called the F-VASI, which measures how much depigmented (colour-lost) skin remains on the face — a lower score means more improvement. The reported data shows that for the main (primary) outcome — how many days until facial skin improvement fell below a meaningful threshold — the figures were not reported for the two groups in Cohort A. For a secondary measure looking at loss of a deeper level of improvement, the vehicle-cream group in Cohort A had a reported time of 195 days, while the figure for the ruxolitinib cream group was not reported. For the secondary outcomes tracking how many participants held on to at least 50%, 75%, or 90% facial improvement across the extension period, the reported data shows the two Cohort A groups (who had been on treatment throughout) generally had higher percentages maintaining improvement — for example, roughly 83–98% still meeting the 50% improvement mark at various timepoints — compared with Cohort B participants who had switched from the dummy cream to ruxolitinib cream partway through, where the reported figures ranged from around 46% to 70% for that same measure at various timepoints. Mean F-VASI scores across the extension period were reported as remaining low (close to zero) in the Cohort A groups, and somewhat higher in the Cohort B groups, with scores ranging from approximately 0.38 to 0.51 in those who had switched from the dummy cream. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04818346 · results posted 5 July 2023

  According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called povorcitinib (tested at three different daily doses — 15 mg, 45 mg, and 75 mg) compared to a placebo (a dummy pill with no active ingredient) in people with vitiligo, a skin condition that causes loss of skin colour. A total of 171 people took part across the four groups at the start of the main 24-week phase. The trial's main question was whether povorcitinib changed the overall extent of vitiligo on the body, measured using a scoring system called the Total Vitiligo Area Scoring Index (T-VASI) — a scale from 0 to 100 where higher numbers mean more skin is affected. The reported data shows that, at 24 weeks, the placebo group's T-VASI score increased slightly on average (about +2.3%), meaning their vitiligo coverage nudged upward. By comparison, the three povorcitinib groups showed average reductions in their scores: roughly −19% for the 15 mg group, −18% for the 45 mg group, and −16% for the 75 mg group. For a secondary measure — the proportion of participants whose T-VASI score fell by 50% or more — the reported figures were 2.3% of the placebo group, 9.3% of the 15 mg group, 11.6% of the 45 mg group, and 4.8% of the 75 mg group. The trial also tracked how many participants experienced any new or worsening medical event (called a treatment-emergent adverse event, or TEAE) while on the study drug. During the first 24-week phase, TEAEs were reported in 24 placebo participants, 29 in the 15 mg group, 30 in the 45 mg group, and 35 in the 75 mg group. During the following 28-week extension phase, TEAEs were reported in 27, 28, 21, and 31 participants in those same groups respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04052425 · results posted 21 September 2022

  According to the results reported on ClinicalTrials.gov, this trial (NCT04052425) looked at a cream called ruxolitinib (1.5% strength, applied twice daily) compared with a "vehicle" cream — an identical-looking cream with no active ingredient — in people with vitiligo, a skin condition that causes patches of skin to lose their colour. The trial had two stages: a 24-week blinded period, where 221 people were randomly assigned to the ruxolitinib cream and 109 to the vehicle cream (neither the participants nor the investigators knew which cream each person was using); followed by a 28-week extension period, where all continuing participants used the ruxolitinib cream. The main thing being measured was how many people saw at least a 75% improvement in the amount of vitiligo on their face, using a standardised scoring system called the F-VASI. The reported data shows that at the end of the 24-week blinded period, approximately 29.8% of participants using the ruxolitinib cream reached that 75% facial improvement mark, compared with 7.4% of those using the vehicle cream. For a less strict threshold — at least 50% facial improvement — the reported figures were 51.2% of the ruxolitinib group versus 16.9% of the vehicle group. For a more demanding threshold of 90% facial improvement, the reported figures were 15.3% versus 2.2%. When looking at the whole body (not just the face), 20.6% of the ruxolitinib group reached the 50% improvement mark, compared with 5.1% of the vehicle group. The reported data also shows that 24.5% of participants in the ruxolitinib group rated their vitiligo as "a lot less noticeable" or "no longer noticeable" on a patient-reported scale, compared with 3.3% in the vehicle group. Finally, the average percentage reduction in the facial area affected by vitiligo was reported as 28.9% in the ruxolitinib group and 9.5% in the vehicle group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04057573 · results posted 21 September 2022

  According to the results reported on ClinicalTrials.gov, this trial (NCT04057573) looked at a cream called ruxolitinib 1.5% in people with vitiligo — a skin condition where patches of skin lose their colour. The trial had two main phases. In the first 24-week phase, 229 people applied ruxolitinib cream twice daily and 115 people applied a "vehicle" cream (an identical-looking cream with no active ingredient) twice daily, without knowing which one they had received. Those who completed this phase then moved into a 28-week extension period where everyone used the ruxolitinib cream. The main thing being measured was how many people saw at least a 75% improvement in the amount of colour-loss on their face, using a scoring system called the F-VASI. The reported data shows that by week 24, about 30.9% of participants using ruxolitinib cream met the main goal of at least 75% improvement in facial vitiligo coverage, compared with 11.4% of those using the vehicle cream. For a less strict target of at least 50% improvement in facial coverage, the reported figures were 51.4% in the ruxolitinib group versus 20.9% in the vehicle group. For a stricter target of at least 90% improvement in facial coverage, the figures were 16.3% versus 1.3%. When looking at the whole body (not just the face), 23.9% of the ruxolitinib group reached the 50% improvement mark, compared with 6.8% in the vehicle group. The reported data also shows results from a patient-rated scale where participants judged how noticeable their vitiligo looked compared to before — about 20.5% of the ruxolitinib group rated their vitiligo as "a lot less noticeable" or "no longer noticeable," versus 4.9% in the vehicle group. On average, the facial area affected by vitiligo changed by −26.4% in the ruxolitinib group and −7.0% in the vehicle group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03715829 · results posted 25 March 2022

  According to the results reported on ClinicalTrials.gov, this trial (NCT03715829) tested different doses of an investigational medicine called PF-06651600 (also known as ritlecitinib) in people with non-segmental vitiligo — a skin condition where patches of skin lose their colour. The main dose-ranging phase enrolled 364 participants across five different dose groups and a placebo group (a dummy treatment with no active ingredient). A separate extension phase then followed, involving up to 293 additional participants across different treatment combinations. The trial's main goal was to measure changes in the amount of facial skin affected by vitiligo using a scoring system called the Facial Vitiligo Area Scoring Index (F-VASI) — a scale where a lower score means less affected skin. The reported data shows that, after 24 weeks, the facial vitiligo scores (F-VASI) changed by the following amounts compared to where participants started: the highest-dose groups (200 mg starting dose and 100 mg starting dose, both stepping down to 50 mg daily) each showed an average reduction of about 21%, the 50 mg daily group showed roughly 18.5% reduction, the 30 mg daily group around 14.6%, and the 10 mg daily group about 3%. The placebo group's score increased by about 2%, meaning on average their facial patches did not reduce. For a secondary measure looking at what share of participants achieved at least a 75% improvement in their facial score, the reported rates were: 12.1% in the highest-dose group, 8.5% and 7.7% in the next two dose groups, 2.7% and 2.3% in the lower-dose groups, and 0% in the placebo group. For whole-body vitiligo scores (T-VASI), the reported percentage changes at 24 weeks were small across all groups, ranging from roughly −2% to −5% in the active-dose groups and −1.4% in the placebo group, with no clear pattern separating the dose groups from placebo on this measure. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04525157 · results posted 21 May 2021

  According to the results reported on ClinicalTrials.gov, this trial (NCT04525157) enrolled 18 participants who received a combination of two treatments: afamelanotide (an implant designed to stimulate skin pigmentation) and NB-UVB (a type of ultraviolet light therapy). The trial was measuring changes in vitiligo — a condition where patches of skin lose their colour — using a scoring system called the Vitiligo Area Scoring Index, or VASI. This score reflects how much of the body's skin surface is affected by vitiligo and how deeply the colour has been lost, with a lower score over time suggesting less affected skin. Of the 18 people who started, 15 completed the trial and 3 did not. The reported data shows that across the various body parts measured, nearly all VASI score changes from the starting point were recorded as 0.00, meaning no change was observed in those areas. The only exception reported was a single measurement of −0.05, which represents a very small numerical decrease in the VASI score for one body region. All results were reported together as a single pooled group, so the data does not break down outcomes by individual participant. It is also worth noting that no secondary outcome measure data appears to have been reported in the structured results submitted to ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT03468855 · results posted 30 November 2020

  According to the results reported on ClinicalTrials.gov, this trial (NCT03468855) enrolled 34 people who used a topical solution called ATI-50002 0.46% on their face. Of those 34 participants, 23 completed the study and 11 did not. The trial was measuring changes in facial depigmentation — that is, the amount of skin that had lost its colour — in a specific area of the face. Depigmentation was scored on a scale from 0 to 100, where 0 means no loss of skin colour and 100 means the entire area has lost colour. On this scale, lower scores represent a better outcome (less depigmentation). The reported data shows that the main (primary) result — measured at 24 weeks — was an average change of +2.0 points on the depigmentation scale compared to where participants started. The secondary measurements tracked changes at several other time points: at week 4 the average change was +0.2 points, at week 8 it was +0.5 points, at week 12 it was +0.3 points, at week 16 it was −0.8 points, and at week 48 it was −1.4 points. A negative number means the group's average depigmentation score went slightly below where it began at that time point, while a positive number means it went slightly above. The reported data does not include information about how meaningful these changes were in a clinical sense, and no comparison group (such as a placebo group) was reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT03933774 · results posted 12 August 2020

  According to the results reported on ClinicalTrials.gov, this trial (NCT03933774) involved 25 people in total — 12 in one group and 13 in another. It was a side-by-side comparison, meaning each participant had tretinoin 0.05% cream applied to one side of the body and a placebo (inactive) cream applied to the other side at the same time. The trial was looking at changes in skin pigmentation (darkening of the skin) after 12 weeks. Of the 25 who started, 21 completed the study — 4 people did not finish (2 from each group). The reported data shows that skin lightness was measured using a special colour-measuring device, which gives a score from 0 (completely dark) to 100 (completely light) — a higher score means lighter skin. At 12 weeks, the group that had tretinoin on the left side and placebo on the right recorded scores of 56.8 (tretinoin side) and 51.0 (placebo side). The group that had placebo on the left and tretinoin on the right recorded scores of 57.6 (tretinoin side) and 54.3 (placebo side). For the secondary outcome, the trial also counted how many participants showed 75% or more repigmentation (meaning a large reduction in skin darkening) at 12 weeks. The reported data shows that in both groups, 8 out of the participants in one group and 9 out of the participants in the other group met this threshold — this figure was the same regardless of which side received the tretinoin cream. It is worth noting that the data as submitted does not separately label which measurement within each group corresponds to the tretinoin versus placebo side for the secondary outcome, so those figures should be interpreted with that limitation in mind. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT00622180 · results posted 5 November 2019

  According to the results reported on ClinicalTrials.gov, this trial enrolled 13 participants in total — six in one group and seven in the other. Because this was a split-body study, each participant received two different light treatments at the same time, one on each side of their body. One group had the Daavlin light device used on their right side and the Excilite device on their left, while the other group had the opposite arrangement. The trial was measuring how much re-pigmentation (the return of skin colour) occurred in targeted skin patches, comparing two types of ultraviolet light therapy: narrowband UVB light and monochromatic excimer light. Ten of the 13 participants completed the study, with three not completing it (reasons were not reported in the data provided). The reported data shows that the primary outcome measured was the percentage of re-pigmentation in the targeted skin areas, assessed using photographs and specialist image analysis software. For participants treated with narrowband UVB light, the reported average re-pigmentation was 0.21 (that is, 21%). For those treated with monochromatic excimer light, the reported average was 0.17 (17%). No secondary outcome measures were included in the data submitted to ClinicalTrials.gov, so no further figures are available to describe. It is worth noting that this was a small study with only 13 participants, and the results as submitted reflect only the numbers reported — no other context, such as how results were measured over time or any other observations, was included in the available data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT02506101 · results posted 11 December 2017

  According to the results reported on ClinicalTrials.gov, this trial (NCT02506101) was designed to compare narrow-band ultraviolet B (UVB) light therapy against no treatment in people with vitiligo — a skin condition where patches of skin lose their colour. The trial planned to measure changes in the extent of skin colour loss using a scoring tool called the Vitiligo Area Scoring Index (VASI), as well as quality of life using two questionnaires, and some tissue-level changes in skin samples. Only 2 participants were enrolled in the light therapy group, and no participants were enrolled in the no-treatment group. Neither of the 2 enrolled participants completed the study. The reported data shows that no outcome measurements were recorded for any of the measures the trial set out to assess — not for the VASI skin scoring, not for either of the two quality-of-life questionnaires, and not for the tissue sample or response stability measures. Because the trial did not complete and no data was collected, there are no numbers to report for any outcome. The data was not reported for any of these measures. In short, according to the results reported on ClinicalTrials.gov, this trial was unable to produce any findings due to the very small number of participants and the fact that none completed the study. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT01992185 · results posted 10 March 2016

  According to the results reported on ClinicalTrials.gov, this trial involved 15 people in total — 7 in the Photocil for Vitiligo group and 8 in the placebo group (who received a low-factor sunscreen, SPF 2). All 15 participants completed the trial with no drop-outs. The trial was measuring something called "percent repigmentation" — in other words, what percentage of skin colour returned to areas affected by vitiligo, a condition where patches of skin lose their pigment. The reported data shows that the Photocil group had an average of 48.5% repigmentation, while the placebo group had an average of 2.5% repigmentation. Only one outcome measure — percent repigmentation — was reported in the submitted results. No secondary outcome data appears to have been submitted to ClinicalTrials.gov, so those figures are not available to report here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT01517893 · results posted 12 March 2015

  According to the results reported on ClinicalTrials.gov, this trial (NCT01517893) looked at whether high-dose simvastatin (a cholesterol-lowering medicine) could help reduce the skin patches caused by vitiligo — a condition where areas of skin lose their colour. A total of 15 people took part: 8 were assigned to receive the active treatment and 7 received a placebo (a dummy treatment with no active ingredient). Of those who started, 5 in the treatment group and all 7 in the placebo group completed the study; 3 people in the treatment group did not finish. The reported data shows that for the main thing being measured — the number of people whose vitiligo-affected skin area shrank by at least one-third (using a scoring tool called the VASI) — the answer was zero in both groups. That is, no participant in either group reached that level of change. For secondary measurements, the reported data shows that one person in the treatment group (and none in the placebo group) had a 30% or more improvement on the doctor's overall assessment, while one person in the placebo group (and none in the treatment group) had the same level of improvement on the patient's own assessment. When looking at a specific tracked skin patch, the treatment group showed an average change of −0.23 cm² (a slight reduction in the affected area) compared to +3.86 cm² in the placebo group (an increase). Quality-of-life scores, measured by a standard skin-condition questionnaire where higher scores mean a bigger impact on daily life, dropped by an average of 3.4 points in the treatment group and 2.3 points in the placebo group — a drop meaning participants reported less impact over time. The reported data also shows that no participants in either group experienced signs of toxicity based on monitored blood tests or symptoms. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

• NCT01262547 · results posted 31 October 2014

  According to the results reported on ClinicalTrials.gov, this trial (NCT01262547) enrolled 3 participants, all of whom had vitiligo — a skin condition where patches of skin lose their colour. All 3 participants completed the study. The trial was testing a skin procedure called dermabrasion-micrografting (where skin is lightly resurfaced and tiny skin grafts are transplanted) compared to dermabrasion alone and an untreated control area, measuring changes in skin repigmentation (the return of skin colour) over 24 weeks using a scoring tool called the Target VASI score. This score runs from 0 (no change in colour return) to 6 (complete colour return). The reported data shows that both the dermabrasion-micrografting group and the dermabrasion-alone group recorded an average change in score of 0.33 points on that 0–6 scale at 24 weeks, while the untreated control group recorded a change of 0 points. In plain terms, both treated areas showed a small numerical change from their starting scores, while the untreated areas showed no numerical change. For the secondary outcome, the reported data shows that 2 out of 3 participants in both the dermabrasion-micrografting group and the dermabrasion-alone group reported redness, while 0 participants in the control group reported redness. It is worth noting that this was a very small study with only 3 participants, so the numbers reported here are limited in what they can tell us on their own. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  View reported results on ClinicalTrials.gov ↗

See the full Vitiligo page · What changed recently

Not medical advice. These are results as reported by the trial sponsor to a public registry, summarised in plain English. They describe what a trial recorded, not whether a treatment is suitable for any person. Verify anything important against the original registry record and discuss what it means for you with your doctor.